PMGC Holdings Inc. (ELAB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US73017P5089

Price
1.58 USD
Market cap
1.28 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

PMGC Holdings Inc. financials

Fiscal year2025
Revenue590,084.00 USD
Gross profit185,314.00 USD
EBIT-7.58 m USD
Net income-7.75 m USD
Diluted EPS – continuing operations-382.30 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PMGC Holdings Inc.

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.